PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Net income growth under 50% of RVPH's 37.71%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
4.17%
Some D&A expansion while RVPH is negative at -100.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Negative yoy deferred tax while RVPH stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-2.08%
Negative yoy SBC while RVPH is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-115.45%
Negative yoy working capital usage while RVPH is 46.69%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Both negative yoy AP, with RVPH at -16.32%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-68.80%
Negative yoy usage while RVPH is 62.23%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
119.47%
Some yoy increase while RVPH is negative at -173.21%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
9.84%
Some CFO growth while RVPH is negative at -20.10%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth of 98.37% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
We expand invests by 98.37% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
64.41%
Debt repayment growth of 64.41% while RVPH is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-34.38%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.